Jazz Pharmaceuticals Management
Management criteria checks 3/4
Jazz Pharmaceuticals' CEO is Bruce Cozadd, appointed in Jan 2003, has a tenure of 21.92 years. total yearly compensation is $15.34M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.54% of the company’s shares, worth $40.43M. The average tenure of the management team and the board of directors is 5.3 years and 11.6 years respectively.
Key information
Bruce Cozadd
Chief executive officer
US$15.3m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 21.9yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5.3yrs |
| Board average tenure | 11.6yrs |
Recent management updates
Recent updates
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$463m |
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$15m | US$1m | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$17m | US$1m | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$16m | US$1m | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$13m | US$1m | US$239m |
| Sep 30 2020 | n/a | n/a | US$179m |
| Jun 30 2020 | n/a | n/a | US$133m |
| Mar 31 2020 | n/a | n/a | US$280m |
| Dec 31 2019 | US$15m | US$1m | US$523m |
| Sep 30 2019 | n/a | n/a | US$609m |
| Jun 30 2019 | n/a | n/a | US$656m |
| Mar 31 2019 | n/a | n/a | US$486m |
| Dec 31 2018 | US$11m | US$979k | US$447m |
| Sep 30 2018 | n/a | n/a | US$520m |
| Jun 30 2018 | n/a | n/a | US$434m |
| Mar 31 2018 | n/a | n/a | US$447m |
| Dec 31 2017 | US$10m | US$950k | US$488m |
Compensation vs Market: Bruce's total compensation ($USD15.34M) is above average for companies of similar size in the US market ($USD8.04M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
CEO
Bruce Cozadd (60 yo)
21.9yrs
Tenure
US$15,341,235
Compensation
Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 21.9yrs | US$15.34m | 0.54% $ 40.4m | |
| President & COO | 1.2yrs | US$5.43m | 0.028% $ 2.1m | |
| Senior VP & Chief Accounting Officer | 5.3yrs | US$1.40m | no data | |
| Executive VP & Chief Legal Officer | 5.4yrs | US$3.88m | 0.012% $ 907.0k | |
| Executive VP | 5.6yrs | US$4.98m | 0.047% $ 3.5m | |
| Executive VP & CFO | less than a year | no data | 0.020% $ 1.5m | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Executive VP & Chief People Officer | 6.1yrs | no data | no data | |
| Senior Vice President of Sleep & CNS Medicine | no data | no data | no data | |
| Executive VP & Chief Commercial OfficerChief Commercial Officer | 4.8yrs | no data | 0.011% $ 787.3k | |
| Senior Vice President of Corporate Strategy | 5.3yrs | no data | no data | |
| Senior Vice President of Technical Operations | 1.3yrs | no data | 0.0021% $ 157.6k |
5.3yrs
Average Tenure
53yo
Average Age
Experienced Management: JAZZ's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 21.9yrs | US$15.34m | 0.54% $ 40.4m | |
| Independent Director | 20.9yrs | US$513.77k | 0.046% $ 3.4m | |
| Independent Director | 12.9yrs | US$531.27k | 1.93% $ 143.8m | |
| Independent Director | 11.6yrs | US$533.77k | 0.020% $ 1.5m | |
| Independent Director | 15.4yrs | US$526.27k | 0.035% $ 2.6m | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | 14.6yrs | US$571.27k | 0.015% $ 1.1m | |
| Independent Non-Executive Director | 4yrs | US$533.77k | 0.0089% $ 664.6k | |
| Independent Director | less than a year | no data | 0.0025% $ 184.4k | |
| Independent Director | 11.6yrs | US$543.77k | 0.025% $ 1.9m | |
| Independent Non-Executive Director | 4yrs | US$521.27k | 0.0089% $ 664.6k | |
| Independent Director | 5.8yrs | US$523.77k | 0.018% $ 1.4m |
11.6yrs
Average Tenure
61.5yo
Average Age
Experienced Board: JAZZ's board of directors are seasoned and experienced ( 11.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Richard Silver | Barclays |